Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol

Clinical Pharmacokinetics
Richard O DayKenneth M Williams


Allopurinol is the drug most widely used to lower the blood concentrations of urate and, therefore, to decrease the number of repeated attacks of gout. Allopurinol is rapidly and extensively metabolised to oxypurinol (oxipurinol), and the hypouricaemic efficacy of allopurinol is due very largely to this metabolite. The pharmacokinetic parameters of allopurinol after oral dosage include oral bioavailability of 79 +/- 20% (mean +/- SD), an elimination half-life (t((1/2))) of 1.2 +/- 0.3 hours, apparent oral clearance (CL/F) of 15.8 +/- 5.2 mL/min/kg and an apparent volume of distribution after oral administration (V(d)/F) of 1.31 +/- 0.41 L/kg. Assuming that 90 mg of oxypurinol is formed from every 100mg of allopurinol, the pharmacokinetic parameters of oxypurinol in subjects with normal renal function are a t((1/2)) of 23.3 +/- 6.0 hours, CL/F of 0.31 +/- 0.07 mL/min/kg, V(d)/F of 0.59 +/- 0.16 L/kg, and renal clearance (CL(R)) relative to creatinine clearance of 0.19 +/- 0.06. Oxypurinol is cleared almost entirely by urinary excretion and, for many years, it has been recommended that the dosage of allopurinol should be reduced in renal impairment. A reduced initial target dosage in renal impairment is still reasonable, but rece...Continue Reading


May 1, 1978·Clinical Pharmacology and Therapeutics·K HandeB Chabner
Mar 1, 1977·Biochemical Pharmacology·T Spector
Jan 1, 1976·Nephron·D W Cockcroft, M H Gault
Sep 1, 1991·Annals of the Rheumatic Diseases·T YamamotoK Higashino
Aug 1, 1991·British Journal of Clinical Pharmacology·D J BirkettR O Day
Apr 1, 1990·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H Bartelink, J Jassem
Dec 14, 1990·Clinica Chimica Acta; International Journal of Clinical Chemistry·K KanekoI Akaoka
Mar 15, 1990·Clinica Chimica Acta; International Journal of Clinical Chemistry·S ReiterM Knedel
Mar 1, 1990·The Journal of International Medical Research·W P LearyK van der Byl
Jan 1, 1989·Journal of Clinical Pharmacology·T M KittE Tsalikian
Jun 11, 1988·British Medical Journal·M A Birchall, H P Henderson
Jun 11, 1988·British Medical Journal·S H RalstonR D Sturrock
Feb 1, 1988·Scandinavian Journal of Clinical and Laboratory Investigation·G van WaegF Niklasson
Sep 1, 1986·Clinical Pharmacokinetics·G A Murrell, W G Rapeport
Dec 1, 1987·British Journal of Rheumatology·B T EmmersonD B Thomson
Jan 1, 1986·European Journal of Clinical Pharmacology·J N ColinF Dietlin
Mar 1, 1987·The American Journal of Medicine·E W CampionL O DeLabry
Sep 26, 1985·The New England Journal of Medicine·W G BerlingerR Spector
Jan 1, 1974·Advances in Experimental Medicine and Biology·C AuscherF Delbarre
Jul 1, 1968·The American Journal of Medicine·G B ElionG H Hitchings
Feb 1, 1969·Clinica Chimica Acta; International Journal of Clinical Chemistry·H A Simmonds
Oct 1, 1965·Arthritis and Rheumatism·J E Seegmiller
Dec 17, 1984·Klinische Wochenschrift·D P Mertz, R Eichhorn
Jan 1, 1984·Advances in Experimental Medicine and Biology·D J Nelson, G B Elion
Aug 1, 1984·British Journal of Rheumatology·T GibsonP Toseland
Feb 1, 1981·Journal of Pharmacokinetics and Biopharmaceutics·L B SheinerL A Pagliaro
Jan 1, 1982·Cancer Chemotherapy and Pharmacology·S J AppelbaumD Perrier
Jan 1, 1980·Advances in Experimental Medicine and Biology·G B ElionW N Kelley
Sep 1, 1994·Drugs·R O DayP M Brooks
Jun 1, 1995·Metabolism: Clinical and Experimental·T YamamotoK Higashino
Oct 1, 1993·The Journal of Pharmacy and Pharmacology·R D Purves
Feb 1, 1994·Clinical Immunology and Immunopathology·G L BradenM Ballow
Jan 1, 1993·European Journal of Clinical Pharmacology·F O MüllerM van Dyk
Apr 1, 1996·British Journal of Clinical Pharmacology·S GrahamD J Birkett
Feb 1, 1997·British Journal of Clinical Pharmacology·D J BirkettR O Day
Jul 17, 1998·Clinical and Experimental Dermatology·H HamanakaM Shimizu
Sep 11, 1999·Clinica Chimica Acta; International Journal of Clinical Chemistry·Y ShibutaniK Higashino
Dec 3, 1999·British Journal of Clinical Pharmacology·K TurnheimR Oberbauer

❮ Previous
Next ❯


Mar 12, 2013·European Journal of Clinical Pharmacology·Daniel F B WrightNicholas H G Holford
Nov 7, 2007·Pediatric Surgery International·Igor SukhotnikJorge G Mogilner
Mar 7, 2014·Drug Design, Development and Therapy·Tadashi SofueMasakazu Kohno
Jan 16, 2008·Clinical Pharmacokinetics·Sophie L StockerRichard O Day
Jan 19, 2011·Clinical Pharmacokinetics·Garry G GrahamKenneth M Williams
Jul 23, 2013·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Sheena N RamasamyRichard O Day
Apr 17, 2008·Scandinavian Journal of Rheumatology·F Perez-Ruiz, N Schlesinger
May 9, 2014·Expert Opinion on Drug Metabolism & Toxicology·Pascal RichetteThomas Bardin
Sep 30, 2015·Nature Reviews. Rheumatology·Lisa K StampJames Yun
Oct 10, 2015·British Journal of Clinical Pharmacology·Daniel F B WrightLisa K Stamp
Nov 12, 2014·Annual Review of Medicine·Rebecca PavlosElizabeth Phillips
Apr 8, 2014·Rheumatic Diseases Clinics of North America·Yashaar ChaichianMichael A Becker
Oct 28, 2014·The FEBS Journal·Swagatika SahooInes Thiele
May 9, 2012·Seminars in Arthritis and Rheumatism·Rodolfo V Curiel, Nicolas J Guzman
Oct 1, 2011·The Journal of Pain : Official Journal of the American Pain Society·Howard S SmithJoshua M Smith
Nov 13, 2008·Journal of Veterinary Pharmacology and Therapeutics·A J van DijkJ Fink-Gremmels
Jan 28, 2009·Journal of the American Geriatrics Society·Joseph T HanlonSteven M Handler
Oct 17, 2012·Cell Biochemistry and Function·Lucas PanizDiogo O Souza
Feb 4, 2012·British Journal of Clinical Pharmacology·Sophie L StockerRichard O Day
Oct 26, 2012·Journal of Cachexia, Sarcopenia and Muscle·Vanessa C VaughanPaul A Lewandowski
Sep 8, 2015·Rheumatology International·Fernando Perez-RuizMaria Angeles Aniel-Quiroga
Apr 18, 2013·British Journal of Clinical Pharmacology·Garry G GrahamRichard O Day
Sep 1, 2014·Clinical Pharmacology in Drug Development·Sally A Helmy, Heba M El-Bedaiwy
Jun 15, 2016·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Robert S Foti, Deepak K Dalvie
Sep 30, 2016·European Journal of Clinical Pharmacology·Daniel Fb WrightLisa K Stamp
Dec 9, 2016·Expert Opinion on Drug Metabolism & Toxicology·Richard O DayGarry G Graham
Jan 26, 2017·Drugs·Talla A RousanUdho Thadani
Oct 19, 2016·Clinical Pharmacokinetics·Bishoy KamelRichard O Day
May 2, 2017·Biological & Pharmaceutical Bulletin·Hiroyoshi KoideTomohiro Terada
Apr 19, 2017·British Journal of Clinical Pharmacology·Diluk R W KannangaraRichard O Day
Mar 13, 2017·Cell Biology and Toxicology·Akira NakajimaTsuyoshi Yokoi
Mar 16, 2016·Therapeutic Advances in Chronic Disease·José Antonio BernalEliseo Pascual
Jul 19, 2013·Circulation. Heart Failure·Michael M GivertzEugene Braunwald

❮ Previous
Next ❯

Related Concepts

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Hereditary Sensory Autonomic Neuropathy

Hereditary Sensory Autonomic Neuropathies are a group of inherited neurodegenerative disorders characterized clinically by loss of sensation and autonomic dysfunction. Here is the latest research on these neuropathies.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Landau-Kleffner Syndrome

Landau Kleffner syndrome (LKS), also called infantile acquired aphasia, acquired epileptic aphasia, or aphasia with convulsive disorder, is a rare childhood neurological syndrome characterized by the sudden or gradual development of aphasia (the inability to understand or express language) and an abnormal electroencephalogram. Discover the latest research on LKS here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.


Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Regulation of Vocal-Motor Plasticity

Dopaminergic projections to the basal ganglia and nucleus accumbens shape the learning and plasticity of motivated behaviors across species including the regulation of vocal-motor plasticity and performance in songbirds. Discover the latest research on the regulation of vocal-motor plasticity here.